In:
World Journal of Surgical Oncology, Springer Science and Business Media LLC, Vol. 21, No. 1 ( 2023-03-03)
Abstract:
The optimal management of rectal cancer with synchronous liver metastases remains debatable. Thus, we propose an optimised liver-first (OLF) strategy that combines concomitant pelvic irradiation with hepatic management. This study aimed to evaluate the feasibility and oncological quality of the OLF strategy. Materials and methods Patients underwent systemic neoadjuvant chemotherapy followed by preoperative radiotherapy. Liver resection was performed in one step (between radiotherapy and rectal surgery) or in two steps (before and after radiotherapy). The data were collected prospectively and analysed retrospectively as intent to treat. Results Between 2008 and 2018, 24 patients underwent the OLF strategy. The rate of treatment completion was 87.5%. Three patients (12.5%) did not proceed to the planned second-stage liver and rectal surgery because of progressive disease. The postoperative mortality rate was 0%, and the overall morbidity rates after liver and rectal surgeries were 21% and 28.6%, respectively. Only two patients developed severe complications. Liver and rectal complete resection was performed in 100% and 84.6%, respectively. A rectal-sparing strategy was performed in 6 patients who underwent local excision ( n = 4) or a watch and wait strategy ( n = 2). Among patients who completed treatment, the median overall and disease-free survivals were 60 months (range 12–139 months) and 40 months (range 10–139 months), respectively. Eleven patients (47.6%) developed recurrence, among whom five underwent further treatment with curative intent. Conclusion The OLF approach is feasible, relevant, and safe. Organ preservation was feasible for a quarter of patients and may be associated with reduced morbidity.
Type of Medium:
Online Resource
ISSN:
1477-7819
DOI:
10.1186/s12957-023-02946-6
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2023
detail.hit.zdb_id:
2118383-1
